Dynamic regulation of FGF23 by Fam20C phosphorylation, GaINAc-T3 glycosylation, and furin proteolysis


The family with sequence similarity 20, member C (Fam20C) has recently been identified as the Golgi casein kinase. Fam20C phosphorylates secreted proteins on Ser-x-Glu/pSer motifs and loss-of-function mutations in the kinase cause Raine syndrome, an often-fatal osteosclerotic bone dysplasia. Fam20C is potentially an upstream regulator of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), because humans with Fam20C mutations and Fam20C KO mice develop hypophosphatemia due to an increase in full-length, biologically active FGF23. However, the mechanism by which Fam20C regulates FGF23 is unknown. Here we show that Fam20C directly phosphorylates FGF23 on Ser(180), within the FGF23 R180XKR179FsX180AE subtilisin-like proprotein convertase motif. This phosphorylation event inhibits O-glycosylation of FGF23 by polypeptide N-acetylgalactosaminyltransferase 3 (GaINAc-T3), and promotes FGF23 cleavage and inactivation by the subtilisin-like proprotein convertase furin. Collectively, our results provide a molecular mechanism by which FGF23 is dynamically regulated by phosphorylation, glycosylation, and proteolysis. Furthermore, our findings suggest that cross-talk between phosphorylation and O-glycosylation of proteins in the secretory pathway may be an important mechanism by which secreted proteins are regulated.

phosphate homeostasis | rickets | Fam20C | familial tumoral calcinosi | chronic kidney disease

Protein kinases are evolutionarily conserved enzymes that regulate numerous cellular processes by transferring a molecule of phosphate from ATP to target substrates (1, 2). The vast majority of these enzymes function within the nucleus and cytosol. In contrast, there are several examples of phosphorylated proteins that are secreted from the cell, which raises the question: What are the kinases that phosphorylate these secreted phosphoproteins? We recently identified a small family of secretory pathway kinases that phosphorylate secreted proteins and proteoglycans (3). These enzymes have N-terminal signal sequences that direct them to the lumen of the endoplasmic reticulum, where they encounter the proteins or proteoglycans that they phosphorylate. One member of this atypical kinase family is the family with sequence similarity 20, member C (Fam20C), which phosphorylates secreted proteins on Ser(S)-x-Glu(E)/pSer(pS) (S-x-E/pS) motifs (3, 4). Because Fam20C localizes within the secretory pathway and the vast majority of secreted phosphoproteins are phosphorylated on S-x-E/pS motifs, Fam20C has been proposed to play a major role in the generation of the secreted phosphate pool (5–7). For example, ∼75% of human serum and cerebrospinal fluid phosphoproteins are phosphorylated on S-x-E/pS motifs (8, 9). This includes proteins important for tooth and bone formation, as well as numerous hormones. In most cases, the functional importance of these phosphorylation events is unknown.

Loss-of-function mutations in the human Fam20C gene cause Raine syndrome, an often-fatal osteosclerotic bone dysplasia (10, 11). Most Raine patients die within the first few weeks of life. Nonlethal cases have also been reported, and these patients develop hypophosphatemia as a result of elevated levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23) (12). Additionally, Fam20C knockout (KO) mice develop renal phosphate wasting due to an increase in circulating bioactive FGF23 as well as severe hypophosphatemic rickets (13, 14). Thus, Fam20C has been proposed to be a regulator of FGF23; however, the molecular mechanisms underlying the control of this hormone by Fam20C are unclear.

FGF23 is secreted from osteoblasts and osteocytes, and targets the kidney to regulate the reabsorption of phosphate and calcium of 1,25-dihydroxyvitamin D3 (15, 16). FGF23 inhibits renal phosphate transport by activating FGF receptors (FGFRs) in a manner that requires binding the coreceptor α-klotho (α-KL) (17). Binding of FGF23 to FGFRs/α-KL induces urinary excretion of phosphate by decreasing the abundance of the type II sodium-dependent phosphate cotransporters NPT2a and NPT2c (15, 16). Several genetic disorders of renal phosphate wasting are associated with alterations in FGF23 (18). X-linked hypophosphatemia is the most prevalent form of hypophosphatemic rickets (1:20,000), and is caused by loss-of-function mutations in the gene encoding the phosphate-regulating endopeptidase homolog X-linked, which is associated with elevated FGF23 expression (19, 20). A similar situation exists in patients with an autosomal recessive form of hypophosphatemic rickets caused by mutations in the ectonucleotide pyrophosphatase ENPP1 (21) and the Fam20C substrate dentin

Significance

The family with sequence similarity 20, member C (Fam20C) is a secretory pathway-specific kinase that phosphorylates secreted proteins on Ser-x-Glu/pSer motifs. Mutations in human Fam20C cause a devastating childhood disorder known as Raine syndrome. Some patients with Fam20C mutations as well as Fam20C KO mice develop hypophosphatemia due to elevated levels of the phosphate-regulating hormone FGF23. In this paper, we show that Fam20C phosphorylates FGF23 on a Ser-x-Glu motif that lies within a critical region of the hormone. The phosphorylation promotes FGF23 proteolysis by furin by blocking O-glycosylation by polypeptide N-acetylgalactosaminyltransferase 3. Our results have important implications for patients with abnormalities in phosphate homeostasis.

Author contributions: V.S.T., J.L.E., S.E.W., J.X., and J.E.D. designed research; V.S.T., J.L.E., S.E.W., J.X., D.J.G., H.N.A., A.K., V.N., K.E.W., and J.E.D. analyzed data; and V.S.T., K.E.W., and J.E.D. wrote the paper. The authors declare no conflict of interest.

Freely available online through the PNAS open access option.

1. Present address: Molecular, Cellular & Integrative Physiology Graduate Program, Department of Medicine, University of California, Los Angeles, CA 90095.

2. To whom correspondence should be addressed. E-mail: jexdi@ucsd.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1402218111/-/DCSupplemental.
matrix protein 1 (DMP1) (22). These disorders share the common denominator of elevated FGF23.

Other Mendelian disorders of renal phosphate handling have provided important insight into the regulation of FGF23 protein processing. FGF23 is inactivated in the Golgi by proteolysis within a highly conserved subtilisin-like proprotein convertase (SPC) site, \( \gamma \text{IRIT} \) (17) generating inactive N- and C-terminal fragments (23). Gain-of-function missense mutations in FGF23 cause autosomal dominant hypophosphemic rickets (ADHR) (24). These mutations substitute the Arg (R) residues within the SPC cleavage site and render the protein resistant to proteolysis (25). Conversely, loss-of-function mutations in FGF23 cause familial tumoral calcinosis (FTC), a hyperphosphemic disorder characterized by often severe ectopic and vascular calcifications (26). FTC is also caused by loss-of-function mutations in \( \gamma \text{IRIT} \) (17) and \( \gamma \text{TrrpSAEDDSERDPL} \) in the trypsin and chymotrypsin digests, respectively (Fig. 1B and C and Fig. S1). These results suggest that FGF23 processing is a highly regulated and physiologically important process.

Here we demonstrate that Fam20C regulates FGF23 by phosphorylation of Ser180, a residue that neighbors the SPC site (27,17). We show that Ser180 phosphorylation inhibits GalNAc-T3 O-glycosylation of Thr176 (18), thereby promoting furin (PCSK3)-dependent FGF23 proteolysis. Our results provide a plausible molecular mechanism by which loss of Fam20C leads to elevated levels of intact, biologically active FGF23 and subsequent hypophosphatemia. Furthermore, our results suggest that cross-talk between phosphorylation and O-glycosylation of proteins in the secretory pathway may be an important mechanism by which secreted proteins are dynamically regulated.

**Results**

**FGF23 Is Phosphorylated by Fam20C In Vitro and in Cells.** Contemporaneously with our finding that Fam20C is a protein kinase, Wang et al. (13) characterized Fam20C KO mice and demonstrated that these animals develop hypophosphatemic rickets as a result of elevated serum intact, bioactive FGF23. Furthermore, a recent report identified compound heterozygous mutations in \( FAM20C \) in two siblings referred for hypophosphatemia and severe dental demineralization disease (12). Biochemical analysis of the patients’ sera identified elevated intact FGF23. Because FGF23 is inactivated in the Golgi by proteolysis, we generated a HEK293T cell line stably expressing a protease-resistant mutant of FGF23 (FGF23 R176Q) (25). This construct contained a C-terminal Flag tag that allowed us to affinity-purify it from conditioned medium. We then digested FGF23 R176Q with trypsin or chymotrypsin, separated the peptides by liquid chromatography, and analyzed them by mass spectrometry (MS). Tandem mass spectrometry (MS/MS) analysis identified \( ^{18} \text{SpAEEDDSERDPLVNKLPR} \) and \( ^{17} \text{TrpSAEDDSERDPL} \) in the trypsin and chymotrypsin digests, respectively (Fig. 1B and C and Fig. S1). These results suggest that FGF23 is phosphorylated in HEK293T cells on Ser180. Notably, Ser180 lies within a Fam20C S-x-E recognition motif and neighbors the SPC recognition site (Fig. 1A). To test whether Fam20C phosphorylates FGF23, we performed in vitro kinase reactions with recombinant Fam20C and FGF23 R176Q. Fam20C phosphorylated FGF23 R176Q in a time-dependent manner, whereas the catalytically inactive Fam20C D478A mutant failed to incorporate phosphate (Fig. 1D). Furthermore, treatment of purified FGF23 R176Q with recombinant Fam20C increased the relative abundance of Ser180 phosphorylation (Fig. S2). By calculating the area under the selected ion species, we estimated that treatment with Fam20C increased the relative abundance of FGF23 R176Q Ser180 phosphorylation ∼10-fold.

To determine whether Fam20C phosphorylates FGF23 in cells, we used clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) genome-editing technology to delete the \( FAM20C \) gene from the osteoblast-like cell line U2OS (31,32) (Fig. S3A). We generated U6-driven expression cassettes to express single-guide RNAs targeting exon 1 of the human \( FAM20C \) gene for expression in U2OS cells (Fig. S3B and D). Two clones were detected to have insertions/deletions (indels) that resulted in frameshift mutations resulting in premature stop codons (Fig. S3 C and E). Protein immunoblotting with a polyclonal antibody raised against full-length Fam20C detected Fam20C protein in the conditioned medium of native U2OS cells but not the cells that were subjected to genome editing (Fig. 2A). To confirm loss of Fam20C activity, Fam20C phosphorylation status of the Fam20C substrate osteopontin (OPN) was analyzed in control and Fam20C KO cells that were metabolically labeled with \( ^{32} \text{P} \)orthophosphate. V-tagged OPN was immunoprecipitated from conditioned medium, and OPN protein and phosphorylation levels were analyzed by autoradiography. OPN was phosphorylated in control cells, and no detectable phosphorylation was observed in Fam20C KO cells (Fig. 2B).

In U2OS cells, ectopically expressed, C-terminal V5-tagged FGF23 R176Q was O-glycosylated, and we can detect the full-length hormone and the C-terminal fragments in the conditioned medium by protein immunoblotting of V5-immunoprecipitates (Fig. 2C). We transiently transfected V5-tagged FGF23 in control and Fam20C KO cells that we metabolically labeled with \( ^{32} \text{P} \)orthophosphate and analyzed V5-immunoprecipitates from

![Figure 1](https://example.com/fig1.png)

**Fig. 1.** Fam20C phosphorylates FGF23 on Ser180. (A) Schematic representation of human FGF23 indicating the signal peptide (SP), intact FGF23 (iFGF23), N-terminal fragment (nFGF23), and C-terminal fragment (cFGF23). The residues surrounding the SPC cleavage site (downward arrow) are shown. Mutations that replace the Arg in patients with autosomal dominant hypophosphemic rickets (ADHR) are also shown. A potential Fam20C phosphorylation site is in red. (B and C) Representative MS/MS fragmentation spectra of a tryptic peptide (FGF23 180–196) depicting Ser180 phosphorylation of FGF23 R176Q purified from conditioned medium of HEK293T cells. (D) Time-dependent incorporation of \( ^{32} \text{P} \) from \( 
\text{γ}_{32} \text{P}\text{ATP} \) into FGF23 R176Q by Fam20C or Fam20C D478A (DA). Reaction products were analyzed by SDS/PAGE and autoradiography.
conditioned medium. FGF23 was phosphorylated in control but not in Fam20C-deficient cells, and phosphorylation was more prevalent within the C-terminal fragment (Fig. 2D). Thus, Fam20C phosphorylates FGF23 in vitro and in cells.

**Phosphorylation of FGF23 at Ser^180 Prevents O-Glycosylation by GalNAc-T3.** The physiological significance of FGF23 O-glycosylation was underscored when inactivating mutations in the gene encoding GalNAc-T3 (GALNT3) were found in patients with FTC (27). Patients with FTC develop hyperparathyreoidism and severe ectopic calcifications, symptoms of which are the metabolic “mirror image” of the hypophosphatemic disorders (26). Subsequent studies identified inactivating mutations in FGF23 in FTC patients without mutations in GALNT3, suggesting that FGF23 and GalNAc-T3 operate in a common pathway to regulate phosphate homeostasis (26). The polypeptide N-acetylgalactosaminytransferase (GalNAc-transferase) family consists of 20 enzymes that catalyze the initial step of mucin-type O-glycosylation by transferring GalNAc from UDP-GalNAc to Ser and Thr (33). GalNAc-T3 O-glycosylation by transferring GalNAc from UDP-GalNAc to Ser and Thr is catalyzed by 20 enzymes that catalyze the initial step of mucin-type O-glycosylation and/or proteolytic processing. To explore the effect of phosphorylation of FGF23 on O-glycosylation and proteolytic processing, we coexpressed Flag-tagged Fam20C or the catalytically inactive Fam20C D478A mutant with V5-tagged FGF23 in U2OS cells and analyzed immunoprecipitates from conditioned medium. Wild-type Fam20C, but not the inactive D478A mutant, decreased the mobility of the C-terminal fragments of FGF23 that was reversed by λ-phosphatase treatment, suggesting a phosphorylation event (Fig. 3A, Lower, first, second, and third lanes). Interestingly, the doublet in full-length, intact FGF23 (iFGF23) was absent when active Fam20C, but not the inactive Fam20C D478A mutant, was expressed (Fig. 3A, Upper, first and second lanes). Given the close proximity of Ser^180 to the SPC site, we reasoned that phosphorylation of FGF23 at Ser^180 would prevent O-glycosylation at Thr^178 and therefore explain the loss of the doublet observed in iFGF23 induced by Fam20C (Fig. 3D, second lane). Indeed, mutation of Ser^180 to Ala prevented the loss of the doublet in iFGF23 when Fam20C was expressed (Fig. 3A, fourth lane). Consistently, mutation of Thr^178 to Ala (a nonglycosylated mutant) or Ser^180 to Asp (a phosphomimetic) resulted in a species that migrated similar to the phosphorylated WT iFGF23 (Fig. 3A, Lower, first, and second lanes). These results suggest that Fam20C phosphorylation of FGF23 at Ser^180 prevents O-glycosylation at Thr^178.

To determine whether phosphorylation of FGF23 Ser^180 directly affects O-glycosylation of FGF23 at Thr^178 by GalNAc-T3, we produced a HEK293T cell line stably expressing a secreted form of GalNAc-T3 lacking the first 37 residues encompassing the transmembrane domain and immunopurified the enzyme from conditioned medium (sGalNAc-T3; residues 38–633; Fig. S4). We then performed in vitro glycosylation experiments with sGalNAc-T3 and a peptide substrate surrounding the SP cleavage site of FGF23 (residues 172–190) of human FGF23, hereafter referred to as FGF23(172–190). MALDI-TOF MS analysis of the reaction products demonstrated that sGalNAc-T3 catalyzed the transfer of GalNAc from UDP-GalNAc to Thr^178 of FGF23(172–190) as expected (Fig. 3B and Figs. S5A and S6). However, when sGalNAc-T3 was assayed against Ser^180-phosphorylated FGF23(172–190), no detectable glycosylation was observed upon extended incubation (Fig. 3C and Fig. S5B). Collectively, our data support that Fam20C phosphorylates FGF23 at Ser^180 and inhibits O-glycosylation by GalNAc-T3 at Thr^178. Importantly, these results provide a molecular mechanism that could account for the increase in serum full-length FGF23 in Fam20C KO mice and in humans with Fam20C mutations, namely reduced Fam20C phosphorylation allowing O-glycosylation and stabilization of FGF23.

**Phosphorylated FGF23 Is Cleaved by the SPC Furin.** The importance of FGF23 cleavage is underscored in patients with ADHR who have mutations that substitute the Arg residues within the SP cleavage site and render the protein resistant to proteolysis (Fig. 1A) (24, 25). As our above results support, phosphorylation of FGF23 at Ser^180 inhibits O-glycosylation and would therefore promote hormone proteolysis and thus inactivation. The specific protease that inactivates FGF23 has yet to be conclusively identified, but is likely a member of the SPC family based upon
the RXXR sequence comprising the cleavage site. With respect to our model, the protease must cleave FGF23 between Arg172 and a phosphorylated Ser180 (Ser180-pSer180-pSer180) (32). To explore the proteolytic processing of phosphorylated FGF23, we coexpressed Flag-tagged PCSK1, PCSK2, and PCSK3 (furin) with V5-tagged FGF23 in U2OS cells. Coexpression of the proteases and FGF23 had no detectable effect on the relative levels of full-length secreted WT FGF23 (Fig. 4A). However, when FGF23 S180D (a phosphomimetic residue) or T178A (an O-glycosylation-defective mutant) was coexpressed with the proteases, the SPC furin completely abolished the FGF23 but did not concurrently increase the levels of the C-terminal fragments (Fig. 4B). Moreover, we analyzed the ability of recombinant furin to cleave the Ser180-phosphorylated FGF23 (172–190) peptide by MALDI-TOF MS. Incubation of the nonphosphorylated or phosphorylated peptide with furin resulted in the time-dependent cleavage of both substrates (Fig. 4C and D and Fig. S8). Thus, phosphorylation of FGF23 at Ser180 preventsThr178 O-glycosylation by GalNAc-T3, which then allows furin-dependent proteolysis.

**Incomplete Inhibition of FGF23 O-Glycosylation by Fam20C T268M.**

Raine syndrome was originally described in 1989 as an aggressive, neonatal osteosclerotic bone dysplasia that results in death within the first few weeks of life (11). Subsequently, mutations in the FAM20C gene were found to be responsible for this disorder (10), and recent reports suggest a broader phenotypic spectrum (11). Subsequently, mutations in the FAM20C gene were found to be responsible for this disorder (10), and recent reports suggest a broader phenotypic spectrum (11). Among the patients with the FAM20C mutations, a subset of the patients presents with a phenotype that could be classified as incomplete Raine syndrome (12). Among these patients, a novel missense mutation in Fam20C that substituted Thr268 to Met (Fam20C T268M) and analysis of the tumor suppressor p53 has been shown to coordinately regulate p53 stability and activity (43). Analogous

Discussion

The results of this study expand our understanding of the complex control of mammalian phosphate homeostasis. Our model for the regulation of FGF23 envisons a highly dynamic interplay between O-glycosylation by GalNAc-T3 (or other members of the GalNAc-transferase family) and phosphorylation by Fam20C as a means by which to balance the processing of FGF23 as intact, biologically active protein (glycosylated > phosphorylated) or N- and C-terminal fragments (phosphorylated > glycosylated) (Fig. S9). This model is consistent with the marked elevation of intact, biologically active FGF23 observed in humans with the Fam20C T268M mutation (12) and in Fam20C KO mice (13, 14).

Sensing the need to adapt phosphate balance in vivo is a complex process, and our data support that the production of bioactive FGF23 will depend upon, in addition to the levels of FGF23 transcription, the relative expression and activities of osteoblast/osteocyte Fam20C, GalNAc-T3, and furin. The mechanisms by which Fam20C is functionally or expressionally regulated are unknown. Recent studies examining the production of intact and/or C-terminal fragments of FGF23 in fibrous dysplasia and during physiological situations of low iron, such as in ADHR (36, 37), support that GalNAc-T3 and furin are likely controlled by multiple factors including 3′,5′-cyclic adenosine monophosphate (38), iron or iron deficiency (39), and inorganic phosphate (40).

Site-specific O-glycosylation within, or neighboring, SPC sites is emerging as an important regulatory mechanism to control SPC-dependent processing of secreted proteins (41). Our results are in accord with the concept that phosphorylation of hormones may promote proteolysis by SPCs (or other proteases) by interfering with O-glycosylation by members of the GalNAc-transferase family. Our observation of competition between phosphorylation and O-glycosylation in the secretory pathway reflects prior observations on the cross-talk between phosphorylation and O-glycosylation by O-linked N-acetylgalactosamine (O-GlcNAc) transferase, which transfers GlcNAc from UDP-GlcNAc to Ser and Thr residues in nuclear and cytosolic proteins (42). Interplay between O-glycosylation and phosphorylation of the tumor suppressor p53 has been shown to coordinately regulate p53 stability and activity (43). Analogous
is possible that Fam20C regulates FGF23 not only through direct phosphorylation and O-glycosylation of proteins in the secretory pathway or whether increased Fam20C activity shifts the FGF23 processing balance toward increased furin proteolysis and hormone inactivation. Furthermore, our data suggest that interplay between phosphorylation and O-glycosylation of proteins in the secretory pathway is critical for the regulated control of circulating FGF23.

In conclusion, we have demonstrated that Fam20C regulates FGF23 by phosphorylation of Ser180. Phosphorylation of FGF23 R176Q, suggesting that other sites may be phosphorylated.

The physiological scenario for the regulated control of circulating FGF23 is likely far more complicated than direct interactions between FGF23, Fam20C, GalNAc-T3, and furin. It is possible that Fam20C regulates FGF23 not only through direct mechanisms, as our results suggest, but also through emerging, indirect pathways. In this regard, we have shown that DMP1, a highly phosphorylated extracellular matrix protein critical for proper mineralization of bone (46), is a substrate for Fam20C (3, 4). Inactivating mutations in DMP1 result in autosomal recessive hypophosphatemic rickets, and Dmp1 KO mice share many phenotypic similarities with those of Fam20C-deficient animals, including elevated FGF23 (13, 22). DMP1 appears to regulate FGF23 expression indirectly, as loss of Dmp1 in vivo impairs the maturation of osteoblasts to osteocytes through unknown mechanisms and results in highly elevated FGF23 mRNA as well as circulating protein (22). Thus, loss of DMP1 phosphorylation in a state of Fam20C deficiency could also contribute to an increase in FGF23 in vivo. Certainly additional studies will be required to understand these new interactions.

In addition to Ser180, three Fam20C consensus X-S-E/pS sites are present in the C-terminal fragment of FGF23 (residues 180–250). We were unable to detect FGF23 peptides surrounding the predicted sites by MS, and therefore at this time we cannot rule out Fam20C-dependent phosphorylation of these residues. By quantitating the incorporated radioactivity in Fig. 1D, we calculated a stoichiometry of about 1.5–2 mol of phosphate per mol FGF23 R176Q, suggesting that other sites may be phosphorylated.

Furthermore, our data suggest that interplay between phosphorylation and O-glycosylation of proteins is critical for the regulated control of circulating FGF23. When BMP15 is expressed in HEK293 cells, phosphorylation and O-glycosylation of proteins in the secretory pathway is critical for the regulated control of circulating FGF23. When BMP15 is expressed in HEK293 cells, phosphorylation and O-glycosylation of proteins in the secretory pathway is critical for the regulated control of circulating FGF23.
pathway may be a critical posttranslational mechanism by which secreted proteins are regulated.

Methods

Protein Purification. Flag-tagged Fam20C and FGFR3 R176Q were immuno-purified from conditioned medium of HEK293T cells as previously described (3). More details on protein purification are presented in SI Methods.

Generation of Anti-Fam20C Antibody. Polyclonal antisera were raised in rabbits against recombinant Flag-tagged Fam20C produced in HEK293T cells that regulate biomineralization. Science 336(6085):1150–1153.


Supporting Information

Tagliabracci et al. 10.1073/pnas.1402218111

SI Methods

Molecular Biology, Cell Culture, and Transfection. Human cDNAs for FGF23, PCSK1, PCSK3 (furin), and the family with sequence similarity 20, member C (Fam20C) were from Open Biosystems. Human PCSK2 and N-acetylgalactosaminyltransferase 3 (GalNAc-T3) cDNAs were from DNASU. The ORFs were amplified by PCR and cloned into mammalian expression plasmids containing a C-terminal V5/His tag (pcDNA4.0; Invitrogen) or a C-terminal Flag tag (pCCF). QuikChange site-directed mutagenesis (Agilent Technologies) was performed to introduce mutations. U2OS and HEK293T cells were grown in DMEM containing 10% (vol/vol) FBS with 100 μg/mL penicillin/streptomycin (GIBCO) at 37 °C with 5% CO2. For coexpression experiments, 5 × 105 cells were seeded in 2 mL in a six-well plate format. Approximately 24 h later, cells were transfected with 0.5 μg pCCF-PCSK1/2/3 or pCCF-Fam20C (or mutants) and 2 μg pcDNA4.0-FGF23 (or mutants) with 7 μL FuGENE 6 (Roche) as recommended by the manufacturer. Forty to 48 h after transfection, the conditioned medium and cell extracts were harvested and analyzed.

Protein Immunoblotting and Immunoprecipitations. V5- and Flag-tagged proteins were analyzed by immunoprecipitation and immunoblotting as described (1). Furin protein was analyzed by immunoblotting cell extracts with an anti-furin polyclonal antibody (1:1,000 dilution; GeneFex). To detect Fam20C protein in conditioned medium, cells were extensively washed with PBS and serum-free DMEM and then incubated for a minimum of 16 h in serum-free DMEM. The medium was centrifuged at 750 g for 5 min to remove cell debris. The supernatant was further centrifuged at 10,000 × g for 10 min, and 100% trichloracetic acid (one-quarter the volume of the medium) was added to the resulting supernatant. The proteins were precipitated overnight at 4 °C and washed two or three times with −20 °C acetone. The samples were dried in a SpeedVac and resuspended in 1× SDS loading buffer. Fam20C protein was analyzed by immunoblotting with a rabbit polyclonal anti-Fam20C antibody.

Generation of Anti-Fam20C Antibody. Anti-Fam20C antibodies were affinity-purified by coupling maltose-binding protein (MBP) fusion peptides to HiTrap NHS-activated HP columns (GE Healthcare). The N-terminal MBP-fusion peptides (residues 20–361, 381–496, 423–584, and 381–584 of human Fam20C) were produced in Escherichia coli and affinity-purified using amylose resin (New England Biolabs).

Metabolic Radiolabeling of U2OS Cells. For metabolic radiolabeling experiments, 5 × 104 cells were seeded in 2 mL in a six-well plate format. Approximately 24 h later, cells were transfected with 5 μg of pcDNA4.0-FGF23 or pcDNA4.0-osteopontin with 10 μL FuGENE 6. Forty to 48 h after transfection, the medium was replaced with phosphate-free DMEM containing 10% (vol/vol) dialyzed FBS and 1 μCi/mL [32P]orthophosphate (PerkinElmer). The cells were incubated for an additional 6–8 h at which time the conditioned medium was centrifuged at 750 × g for 5 min to remove cell debris. The medium was further centrifuged at 10,000 × g for 10 min and V5-tagged proteins were immunoprecipitated from the supernatant, washed five times with PBS containing 0.4 mM EDTA and 1% Nonidet P-40, and then analyzed for protein and incorporated 32P by immunoblotting and autoradiography.

Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Genome Editing. The 20-nt guide sequences targeting human Fam20C and Furin were designed using the clustered regularly interspaced short palindromic repeats (CRISPR) design tool at www.genome-engineering.org/crispr (2) and cloned into a bicistronic expression vector (pX330) containing human codon-optimized Cas9 and the RNA components (2) (Addgene).

The guide sequences targeting exon 1 of human Fam20C and exon 7 of human Furin are shown below.

**FAM20C.**

5′-GGGCTGCGCGACAGAAGACG-3′ (clone 5)
5′-CCGCCCGCAAGGCAGGCT-3′ (clone 9)

**FURIN.**

5′-TACACCAAGACACCGTGT-3′ (clones 17 and 82)

The single-guide RNAs (sgRNAs) in the pX330 vector (4 μg) were mixed with EGFFP (1 μg; Clontech) and cotransfected into U2OS cells using FuGENE 6. Twenty-four hours posttransfection, the cells were trypsinized, washed with PBS, and resuspended in fluorescence-activated cell sorting (FACS) buffer (PBS, 5 mM EDTA, 2% FBS, and 100 μg/mL penicillin/streptomycin). GFP-positive cells were single-cell–sorted by FACS (Human Embryonic Stem Cell Core, University of California, San Diego; BD Influx) into a 96-well plate format into DMEM containing 20% FBS and 100 μg/mL penicillin/streptomycin. Single clones were expanded and screened for Fam20C and Furin by protein immunoblotting. Genomic DNA (gDNA) was purified from clones using the Quick-gDNA Prep Kit (Zymo Research), and the region surrounding the protospacer adjacent motif (PAM) was amplified with Q5 polymerase (New England Biolabs) using the following primers (linkers containing EcoRI and HindIII restriction sites are underlined).

**FAM20C.**

Forward: 5′-AAAAAGATTCTTGGAGAGGAGCGCGCTGA-GGATC-3′
Reverse: 5′-AAAAAAAGCTTTCGCGGTCTCCGGCCGCTT-GTG-3′

**FURIN.**

Forward: 5′-AAAAAGATTTCACCTACGGGGATGATGGG-TGTC-3′
Reverse: 5′-AAAAAAGCTTAGAGAAGGAGAAAAAGAGA-ACACCTCC-3′

PCR products were purified using the DNA Clean & Concentrator Kit (Zymo Research) and cloned into pBluescript II KS+. To determine the indels of individual alleles, ~10 bacterial colonies were expanded and the plasmid DNA was purified and sequenced.

Protein Purification. Flag-tagged Fam20C and FGF23 R176Q were immunopurified from conditioned medium of HEK293T cells as previously described (1). FGF23 R176Q was further purified by Superdex 200 size-exclusion chromatography. To generate a secreted form of GalNAc-T3 (GalNAc-T3), the nucleotides encoding residues 38–633 of human GalNAc-T3 were cloned into a modified retroviral (pQCXIP; Clontech) vector containing an N-terminal interleukin 2 signal peptide and a C-terminal Flag
tag. Stable expression and purification of sGalNAc-T3 from conditioned medium were performed as described (1).

Enzyme Assays. Kinase assays. In vitro kinase assays were performed essentially as described (1). The reaction mixture contained 32.5 mM Tris-HCl (pH 7.5), 100 mM NaCl, 12.5% glycerol, 10 mM MnCl₂, 0.5 mM [γ-³²P]ATP (specific activity 100–500 cpm/nmol), 0.5 mg/mL FGF23 R176Q, and 20 μg/mL Fam20C-Flag or Fam20C (D478A)-Flag.

Glycosylation assays. In vitro O-glycosylation assays were performed essentially as described (3). Reactions were performed in a 20-μL mixture containing 25 mM sodium cacodylate (pH 7.4), 10 mM MnCl₂, 1.5 mM UDP-GalNAc (Sigma), 0.5 mg/mL peptide substrate: PIIPRHRHTRSAEDDSERDPL; pFGF23(172–190) or PIIPRHRHPSAEDDSERDPL; pFGF23(172–190), and 50 μg/mL sGalNAc-T3. Reactions were incubated at 37 °C and terminated at the indicated time points by the addition of an equal volume of Sigma-Aldrich universal MALDI matrix re-suspended in 78% acetonitrile and 0.1% trifluoroacetic acid.

Protease assays. Furin cleavage assays were performed as previously described (3). Reactions were performed in a 20-μL mixture containing 50 mM Hepes (pH 7.5), 1 mM CaCl₂, 0.5 mg/mL FGF23(172–190) or pFGF23(172–190), and 0.02 units per μL furin (New England Biolabs). Reactions were incubated at 37 °C and terminated at the indicated time points by the addition of an equal volume of Sigma-Aldrich universal MALDI matrix re-suspended in 78% acetonitrile and 0.1% trifluoroacetic acid.

Deglycosylation and λ-phosphatase assays. V5-immunoprecipitates from conditioned medium of U2OS cells transiently expressing V5-tagged FGF23 were treated with O-glycosidase and PNGase F to remove N-linked glycosylation according to the manufacturer’s instructions (Sigma-Aldrich; Enzymatic Protein Deglycosylation Kit). λ-Phosphatase assays were performed as described (1).

Matrix-Assisted Laser Desorption/Ionization Analysis. Glycosylation and protease reaction products (1 μL) were plated on an Applied Biosciences (ABI) MALDI target plate for analysis. The ABI 4800 MALDI-TOF/TOF was calibrated at 25 ppm mass error with a peptide mix standard. After calibration, each spot was analyzed using reflectron positive ionization and a laser power of 30%. Masses that corresponded to truncated forms of peptide PIIPRHRHTRSAEDDSERDPL; pFGF23(172–190) were sequenced de novo for validation. In addition, b- and y-ion masses were used to localize phosphorylated residues on fragment ions.

Peptide Synthesis. Peptides and phosphopeptides were synthesized by standard O-(Benzytriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate/1-Hydroxybenzotriazole (HBTU/HOBt) Fmoc solid-phase chemistry on Wang resin using an ABI 431A synthesizer and incorporating pSer as its Fmoc-O-benzyl ester. Peptide–resin was cleaved with reagent K (2-Ethyl-5-phenylisoxazolium-3'-sulfonate). Identity and purity were assessed by electrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry; the purity of crude peptide was at least 90%. Peptides were dissolved in 10 mM Hepes and the pH was adjusted to 7 with NaOH before use.

Mass Spectrometry. Fifty picomoles of Flag-tagged FGF23 R176Q was oxidized with 4 mM DTT and alkylated with 8 mM iodoacetamide and digested with either trypsin, endoproteinase Gluc, or chymotrypsin. The resulting peptide extract was diluted into a solution of 2% acetonitrile, 0.1% formic acid (buffer A) for analysis. Two picomoles of each digest was analyzed by automated microcapillary liquid chromatography-tandem mass spectrometry. Fused-silica capillaries (100-μm inner diameter; i.d.) were pulled using a P-2000 CO₂ laser puller (Sutter Instruments) to a 5-μm i.d. tip and packed with 10 cm of 5-μm Magic C18 material (Agilent) using a pressure bomb. This column was then installed in-line with a Dionex 3000 HPLC pump running at 300 nL/min. Peptides were loaded with an autosampler directly onto the column and were eluted from the column by applying a 30-min gradient from 5% buffer B to 40% buffer B (98% acetonitrile, 0.1% formic acid). The gradient was switched from 40% to 80% buffer B over 5 min and held constant for 3 min. Finally, the gradient was changed from 80% buffer B to 100% buffer A over 0.1 min, and then held constant at 100% buffer A for 15 more minutes. The application of a 1.8-kV distal voltage electro-sprayed the eluting peptides directly into an LTQ XL ion trap mass spectrometer equipped with a nano-liquid chromatography-electrospray ionization source. Full mass spectra were recorded on the peptides over 400–2,000 m/z, followed by five tandem mass (MS/MS) events on the five most intense ions. Mass spectrometer scan functions and HPLC solvent gradients were controlled by the Xcalibur data system (Thermo Finnigan). MS/MS spectra were extracted with ReAdW.exe (http://sourceforge.net/projects/sashimi). The resulting mzXML file contains all of the data for all MS/MS spectra and can be read by the subsequent analysis software. The MS/MS data were searched with Inspect (4) against a database containing protein sequences for all E. coli proteins, common contaminants, and the sequence for FGF23 R176Q (2,786 proteins) with modifications: +16 on methionine (oxidation), +57 on cysteine (carbamidomethyl), and +80 on threonine, serine, or tyrosine (phosphorylation). Only peptides with at least a P value of 0.01 were analyzed further. The MS/MS data of putative phosphorylated peptides were manually verified. In addition, further verification was performed by analyzing putative phosphorylated peptides in targeted MS/MS mode.

Fig. S1. FGF23 is phosphorylated on Ser\textsuperscript{180}. Representative MS/MS fragmentation spectra of a chymotryptic peptide (FGF23 178–190) depicting Ser\textsuperscript{180} phosphorylation of FGF23 R176Q purified from conditioned medium of HEK293T cells. The nonphosphopeptide and the phosphopeptide are shown in A and B, respectively.

Fig. S2. Fam20C phosphorylates FGF23 on Ser\textsuperscript{180}. Selected ion chromatograms of tryptic peptides (FGF23 180–196) from FGF23 R176Q (A) or FGF23 R176Q that had been treated with recombinant Fam20C (B). Note the relative 10-fold increase in the relative abundance of the phosphopeptide upon treatment with Fam20C. Calculations are estimated based on the areas under the curve for the selected ion species (AA phospho/nonphospho; 38,501/812,455 = 0.05; 340,573/714,375 = 0.5). AA and MA, area; RT, retention time.
**Fig. S3.** Generation of Fam20C knockout cells using CRISPR/Cas9 genome editing. (A) The type II prokaryotic CRISPR/Cas9 from Streptococcus pyogenes has been shown to facilitate RNA-guided site-specific DNA cleavage and can be harnessed to target the destruction of specific genes in mammalian cells (1–3). Any genomic locus followed by a 5′-NGG PAM (red) can be targeted by a chimeric single guide RNA (sgRNA) (green) consisting of a 20-nt guide sequence and a scaffold. The sgRNA directs the Cas9 nuclease (gray) to the genomic target, resulting in a double-strand break. The double-strand break is repaired by error-prone nonhomologous end joining or by homologous recombination. (B and D) Schematic representations of the base pairing between guide RNAs and the targeting locus of exon 1 in the human Fam20C gene. (C and E) The sequences of the mutated alleles in Fam20C clone 5 (C) and clone 9 (E) and representative chromatograms depicting the indels (red) are shown. The indels are predicted to cause frameshift mutations producing inactive copies of the protein. SP, signal peptide.

Fig. S4. Expression and purification of sGalNAc-T3. SDS/PAGE and Coomassie staining of Flag-tagged sGalNAc-T3 immunopurified from the conditioned medium of HEK293T cells.
Fig. S5. Ser\textsuperscript{180}-phosphorylated FGF23(172–190) is not a substrate for sGalNAc-T3. Full MALDI-TOF MS spectra depicting the time-dependent incorporation of GalNAc from UDP-GalNAc into FGF23(172–190) (A) or Ser\textsuperscript{180}-phosphorylated FGF23(172–190) (B).
Fig. S6. Thr^{178} is O-glycosylated by sGalNAC-T3. Representative MS/MS fragmentation spectrum of the selected ion peak at m/z 2450 in Fig. S5A, depicting the addition of GalNAc to Thr^{178}.
Fig. S7. Generation of FURIN knockout cells using CRISPR/Cas9 genome editing. (A and C) Schematic representations of the base pairing between a guide RNA (sgRNA_18) and the targeting locus of exon 7 in the human FURIN gene. (B and D) The sequences of the mutated alleles in FURIN clone 17 (B) and clone 82 (D) and representative chromatograms depicting the indels (red) are shown. The indels are predicted to cause frameshift mutations producing inactive copies of the protein. (E) Protein immunoblotting of cell extracts from control and furin KO cells.
Fig. S8. Ser\textsuperscript{180}-phosphorylated FGF23(172–190) is cleaved by furin. Full MALDI-TOF MS spectra depicting the time-dependent cleavage of FGF23(172–190) (A) or Ser\textsuperscript{180}-phosphorylated FGF23(172–190) (B).
Fig. S9. Model for the regulation of FGF23 by Fam20C. We propose that interplay between phosphorylation by Fam20C (i) and O-glycosylation by GalNAc-T3 (ii) regulates the processing and activity of FGF23 by furin. Phosphorylation of FGF23 at Ser\textsuperscript{180} by Fam20C inhibits GalNAc-T3-mediated O-glycosylation at Thr\textsuperscript{178} and promotes inactivation by furin. Fam20C may also phosphorylate predicted Ser-x-Glu/pSer residues in the C-terminal region of FGF23.